Sunday, July 20, 2025 9:56:02 PM
There’s been a lot of noise lately about a “fabricated quote.” So let’s clear this up, with facts and receipts.
Yes, I originally said the quote came from the 2025 10-K. That was incorrect. I used ChatGPT to help locate it, and it paraphrased a real disclosure from another document. I didn’t realize it wasn’t verbatim at the time. That’s on me.
But nothing was fabricated, not the meaning, not the substance, not the disclosure itself.
The statements in question come directly from Northwest Biotherapeutics’ official February 6, 2024 press release, which is still publicly posted on the company’s website.
Here’s what it actually says:
“Advent BioServices will undertake final qualification and validation of the GMP units and use engineering runs with the system to collect data in order to submit an application to regulators to approve the use of the system for production of DCVax-L for patients.”
And:
“The DCVax-L products manufactured through the Flaskworks system are substantially comparable to the DCVax-L products made through the existing manual process.”
That’s validation, comparability, and regulatory submission, in plain, public English.
📷 Screenshots from the official PR (for anyone who wants to verify):
🔗 https://postimg.cc/gallery/WZKCFSj
📄 Full official press release:
🔗 https://nwbio.com/northwest-biotherapeutics-moves-from-optimization-of-flaskworks-prototype-to-fabrication-of-gmp-compliant-units-for-installation-validation-and-final-testing-prior-to-regulatory-certification/
And here’s the bigger problem:
This board is supposed to be for iHub NWBO investors. But when someone cites an actual company disclosure, they’re attacked. When Danish breaks it down with precision and sources, he gets one post a day. Meanwhile others can post freely and twist the conversation, even after being proven wrong.
This isn’t about accuracy anymore. It’s about controlling what gets seen.
I corrected my sourcing mistake.The quote stands.The disclosure is public. And the double standard is obvious.
Yes, I originally said the quote came from the 2025 10-K. That was incorrect. I used ChatGPT to help locate it, and it paraphrased a real disclosure from another document. I didn’t realize it wasn’t verbatim at the time. That’s on me.
But nothing was fabricated, not the meaning, not the substance, not the disclosure itself.
The statements in question come directly from Northwest Biotherapeutics’ official February 6, 2024 press release, which is still publicly posted on the company’s website.
Here’s what it actually says:
“Advent BioServices will undertake final qualification and validation of the GMP units and use engineering runs with the system to collect data in order to submit an application to regulators to approve the use of the system for production of DCVax-L for patients.”
And:
“The DCVax-L products manufactured through the Flaskworks system are substantially comparable to the DCVax-L products made through the existing manual process.”
That’s validation, comparability, and regulatory submission, in plain, public English.
📷 Screenshots from the official PR (for anyone who wants to verify):
🔗 https://postimg.cc/gallery/WZKCFSj
📄 Full official press release:
🔗 https://nwbio.com/northwest-biotherapeutics-moves-from-optimization-of-flaskworks-prototype-to-fabrication-of-gmp-compliant-units-for-installation-validation-and-final-testing-prior-to-regulatory-certification/
And here’s the bigger problem:
This board is supposed to be for iHub NWBO investors. But when someone cites an actual company disclosure, they’re attacked. When Danish breaks it down with precision and sources, he gets one post a day. Meanwhile others can post freely and twist the conversation, even after being proven wrong.
This isn’t about accuracy anymore. It’s about controlling what gets seen.
I corrected my sourcing mistake.The quote stands.The disclosure is public. And the double standard is obvious.
Bullish
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
